Nanomodified Switch Induced Precise and Moderate Activation of CAR‐T Cells for Solid Tumors (Adv. Sci. 12/2023)

Cancer Immunotherapy In article number 2205044, Baorui Liu, Rutian Li, and co‐workers constructed gelatinase‐responsive NanoSwitch to control the activation process of CAR‐T cells, leading to on‐site activation of CAR‐T cells at the tumor region in a sustainable way. This platform has promising pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xinyue, Meng, Fanyan, Li, Xiang, Xue, Luxin, Chen, Anni, Qiu, Yuling, Zhang, Zhifan, Li, Lin, Liu, Fengcen, Li, Yishan, Sun, Zhichen, Chu, Yanhong, Xu, Ruihan, Yu, Lixia, Shao, Jie, Tian, Manman, Qian, Xiaoping, Liu, Qin, Liu, Baorui, Li, Rutian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Back Cover
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10131794/
http://dx.doi.org/10.1002/advs.202370074
Descripción
Sumario:Cancer Immunotherapy In article number 2205044, Baorui Liu, Rutian Li, and co‐workers constructed gelatinase‐responsive NanoSwitch to control the activation process of CAR‐T cells, leading to on‐site activation of CAR‐T cells at the tumor region in a sustainable way. This platform has promising potential to prevent the main obstacles in the CAR‐T therapy for solid tumors including cytokine‐release syndrome and on‐target/off‐tumor toxicity. [Image: see text]

Ejemplares similares